Xilio Therapeutics, Inc. (XLO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 18, 2024, by Xilio Therapeutics, Inc., a Delaware corporation and emerging growth company. The filing reports on the completion of a private placement transaction with Gilead Sciences, Inc., the release of preliminary Phase 1 clinical data for its lead asset XTX301, and an update to its financial runway.
Key Financial Metrics and Transaction Details
The Company completed the final tranche of a stock purchase agreement with Gilead Sciences, Inc., reaching the maximum aggregate investment of $25.0 million. The specific details of the December 18, 2024 transaction are as follows:
- Securities Issued: 1,759,978 shares of common stock and prefunded warrants to purchase 6,092,816 shares.
- Purchase Price: $1.04 per share for common stock; $1.0399 per share for prefunded warrants.
- Gross Proceeds: Approximately $8.2 million from this specific closing.
- Total Investment: The cumulative investment from Gilead under the agreement is now approximately $25.0 million.
The filing does not provide specific values for revenue, net profit, operating cash flow, or debt levels for the period, as this is a current report focused on specific events rather than a periodic financial statement.
Material Changes and Clinical Updates
On December 19, 2024, the Company announced preliminary data from its ongoing Phase 1 clinical trial evaluating XTX301 (also referred to as XTX101 in the text), a tumor-activated IL-12, in patients with advanced solid tumors. This represents a significant milestone in the Company's clinical development program.
Guidance, Outlook, and Risks
Financial Outlook: Following the receipt of the $8.2 million in proceeds from the December 18 closing, management anticipates that existing cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into the third quarter of 2025.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding market conditions, clinical trial outcomes, and the ability to meet financial projections. The Company explicitly disclaims any obligation to update these statements except as required by law.
Key Facts for Investor Verification
- Verify the total cash balance and burn rate in the most recent Form 10-Q to confirm the runway extension into Q3 2025.
- Review the full text of the press release (Exhibit 99.2) for detailed efficacy and safety data regarding the XTX301 Phase 1 trial.
- Confirm the dilution impact of the 1,759,978 shares and 6,092,816 prefunded warrants issued to Gilead.
- Check the terms of the prefunded warrants, specifically the 19.9% beneficial ownership limitation on exercise.